ZEVRA THERAPEUTICS INC (ZVRA) — insider trading
Health Care · NASDAQ
ZEVRA THERAPEUTICS INC (ZVRA) has 21 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 21 (latest 2026-08-14).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Thompson Rahsaan | Officer (Chief Legal & Compliance) | Open-market sale | 42,666 | $11.13 | $474.8K | Form 4 |
| 2026-08-10 | Watton Corey Michael | Director | Option exercise / conversion (derivative) | 12,300 | — | $0 | Form 4 |
| 2026-08-10 | Watton Corey Michael | Director | Open-market sale | 12,300 | $11.25 | $138.4K | Form 4 |
| 2026-08-10 | Watton Corey Michael | Director | Option exercise / conversion | 12,300 | $4.97 | $61.1K | Form 4 |
| 2026-06-22 | Thompson Rahsaan | Officer (Chief Legal & Compliance) | Open-market sale | 34,557 | $12.68 | $438.3K | Form 4 |
| 2026-06-21 | Thompson Rahsaan | Officer (Chief Legal & Compliance) | Option exercise / conversion (derivative) | 66,667 | — | $0 | Form 4 |
| 2026-06-21 | Thompson Rahsaan | Officer (Chief Legal & Compliance) | Option exercise / conversion | 66,667 | — | — | Form 4 |
| 2026-06-04 | Shih Alvin | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-04 | Anderson Thomas | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-04 | Calder Douglas W | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-04 | Watton Corey Michael | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-04 | Secor Alicia | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-06-04 | FAVORITO TAMARA A | Director | Grant / award / vesting (derivative) | 30,000 | — | $0 | Form 4 |
| 2026-05-28 | Sangiovanni Timothy J. | Officer (SVP, Finance & Corp Controller) | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-05-28 | Sangiovanni Timothy J. | Officer (SVP, Finance & Corp Controller) | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-05-11 | Thompson Rahsaan | Officer (Chief Legal & Compliance) | Open-market sale | 1,794 | $11.30 | $20.3K | Form 4 |
| 2026-03-24 | Bode John B | Director | Option exercise / conversion (derivative) | 39,200 | — | $0 | Form 4 |
| 2026-03-24 | Bode John B | Director | Option exercise / conversion (derivative) | 39,200 | — | $0 | Form 4 |
| 2026-03-24 | Bode John B | Director | Option exercise / conversion | 39,200 | $4.89 | $191.7K | Form 4 |
| 2026-03-24 | Bode John B | Director | Option exercise / conversion | 39,200 | $4.97 | $194.8K | Form 4 |
| 2026-03-18 | Renz Justin A | Officer (CFO) | Grant / award / vesting (derivative) | 300,000 | — | $0 | Form 4 |
Ask the chat about ZVRA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ZEVRA THERAPEUTICS INC (ZVRA).
Last updated 2026-08-14 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.